International Stem Cell Corporation to Present at BIO 2014

CARLSBAD, CA--(Marketwired - Jun 17, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw, will present an overview of ISCO and its subsidiaries at the BIO 2014 conference on Tuesday, June 24th at 4:15 pm PDT. The conference is being held at the San Diego Convention Center.

BIO 2014 conference presentation details:
Date: Tuesday, June 24^th 2014
Time: 4:15 pm PDT
Location: San Diego Convention Center, San Diego, CA
Room: Mission Beach
Conference details: http://convention.bio.org/

BIO is the largest, most influential biotech meeting in the world, regularly attracting 15,000 of the most powerful biotech and pharm participants from 60+ countries. This year at the San Diego Convention Center, June 23 - 26, 2014, the conference includes sessions and specialty forums covering 17 hot topics, 1,700+ exhibitors and BIO One-on-One Partnering™ meetings with thousands of companies. If you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team please contact the conference organizers. To register for the event visit the conference website at http://convention.bio.org/register/

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell